1. Home
  2. RYTM vs SYNA Comparison

RYTM vs SYNA Comparison

Compare RYTM & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • SYNA
  • Stock Information
  • Founded
  • RYTM 2008
  • SYNA 1986
  • Country
  • RYTM United States
  • SYNA United States
  • Employees
  • RYTM N/A
  • SYNA N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • SYNA Computer peripheral equipment
  • Sector
  • RYTM Health Care
  • SYNA Technology
  • Exchange
  • RYTM Nasdaq
  • SYNA Nasdaq
  • Market Cap
  • RYTM 6.4B
  • SYNA 2.7B
  • IPO Year
  • RYTM 2017
  • SYNA 2002
  • Fundamental
  • Price
  • RYTM $97.17
  • SYNA $71.85
  • Analyst Decision
  • RYTM Strong Buy
  • SYNA Strong Buy
  • Analyst Count
  • RYTM 13
  • SYNA 7
  • Target Price
  • RYTM $101.92
  • SYNA $92.17
  • AVG Volume (30 Days)
  • RYTM 548.5K
  • SYNA 364.0K
  • Earning Date
  • RYTM 11-04-2025
  • SYNA 11-06-2025
  • Dividend Yield
  • RYTM N/A
  • SYNA N/A
  • EPS Growth
  • RYTM N/A
  • SYNA N/A
  • EPS
  • RYTM N/A
  • SYNA N/A
  • Revenue
  • RYTM $156,287,000.00
  • SYNA $1,074,300,000.00
  • Revenue This Year
  • RYTM $44.69
  • SYNA $11.05
  • Revenue Next Year
  • RYTM $63.53
  • SYNA $9.89
  • P/E Ratio
  • RYTM N/A
  • SYNA N/A
  • Revenue Growth
  • RYTM 53.55
  • SYNA 11.98
  • 52 Week Low
  • RYTM $45.91
  • SYNA $41.80
  • 52 Week High
  • RYTM $106.52
  • SYNA $89.81
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 49.52
  • SYNA 59.21
  • Support Level
  • RYTM $94.39
  • SYNA $69.83
  • Resistance Level
  • RYTM $102.46
  • SYNA $74.49
  • Average True Range (ATR)
  • RYTM 3.18
  • SYNA 2.01
  • MACD
  • RYTM -1.37
  • SYNA 0.10
  • Stochastic Oscillator
  • RYTM 22.88
  • SYNA 69.22

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About SYNA Synaptics Incorporated $0.001 Par Value

Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.

Share on Social Networks: